BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31404445)

  • 21. Double-hit B-cell lymphomas.
    Aukema SM; Siebert R; Schuuring E; van Imhoff GW; Kluin-Nelemans HC; Boerma EJ; Kluin PM
    Blood; 2011 Feb; 117(8):2319-31. PubMed ID: 21119107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].
    Misyurina AE; Kravchenko SK; Kovrigina AM; Magomedova AU; Plastinina LV; Obukhova TN; Misyurin AV; Misyurin VA; Grebenuk LA; Babaeva FE; Baryakh EA; Vorobiev AI
    Ter Arkh; 2019 Jul; 91(7):52-62. PubMed ID: 32598736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements.
    Sesques P; Johnson NA
    Blood; 2017 Jan; 129(3):280-288. PubMed ID: 27821509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphological, immunophenotypic and molecular characterization of mature aggressive B-cell lymphomas in Chinese pediatric patients.
    Lu B; Zhou C; Yang W; Huang H; Gao Z; He Y; Liu H; Zhou X; Gong L
    Leuk Lymphoma; 2011 Dec; 52(12):2356-64. PubMed ID: 21740296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.
    Alsuwaidan A; Pirruccello E; Jaso J; Koduru P; Garcia R; Krueger J; Doucet M; Chaudhry R; Fuda F; Chen W
    Cytometry B Clin Cytom; 2019 Sep; 96(5):368-374. PubMed ID: 30734478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.
    He M; Gao L; Zhang S; Tao L; Wang J; Yang J; Zhu M
    Gastric Cancer; 2014; 17(3):431-41. PubMed ID: 24232982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
    Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
    Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms-Updated Classification and New Concepts.
    Kurz KS; Ott M; Kalmbach S; Steinlein S; Kalla C; Horn H; Ott G; Staiger AM
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
    Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
    Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
    Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Essential roles of sphingosine 1-phosphate receptor types 1 and 3 in human hepatic stellate cells motility and activation.
    Liu X; Yue S; Li C; Yang L; You H; Li L
    J Cell Physiol; 2011 Sep; 226(9):2370-7. PubMed ID: 21660960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of sphingosine-1-phosphate receptor 2 is correlated with migration and invasion of human colon cancer cells: A preliminary clinical study.
    Yan J; Chen Y; Wu Q; Shao L; Zhou X
    Oncol Lett; 2022 Jul; 24(1):241. PubMed ID: 35720474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
    Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
    Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
    Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
    Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
    Swerdlow SH
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
    Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with
    Olschewski V; Witte HM; Bernard V; Steinestel K; Peter W; Merz H; Rieken J; Biersack H; von Bubnoff N; Feller AC; Gebauer N
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis.
    Choi SY; Kim SJ; Kim WS; Kim K; Ko YH
    Virchows Arch; 2011 Nov; 459(5):495-502. PubMed ID: 22002677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.